Acumen Pharmaceuticals, Inc. Q4 FY2024 earnings call

• Dan O’Connell highlighted the successful enrollment in ALTITUDE AD Phase 2 study, with 542 participants enrolled, and expects topline results in late 2026.
• Completed Phase 1 study on subcutaneous sabirnetug, showing it's well tolerated with systemic exposure supporting further development.
• INTERCEPT-AD Phase 1 manuscript and related fluid biomarker publication released.
• Use of plasma p-tau 217 assay in ALTITUDE-AD improved enrollment efficiency.
• Committed to advancing sabirnetug development through medical conferences and peer-reviewed publications.

No specific product segment financials provided. The focus is on the sabirnetug program, with key developments related to its clinical trials and formulations.

• Ended 2024 with $231.5 million in cash and marketable securities, expected to support activities into first-half 2027.
• Enrollment complete in ALTITUDE AD Phase 2 trial, with topline results expected in late 2026.

Q: Jason Zemansky asked about preclinical AD and subcutaneous formulation in ALTITUDE AD.

A: Dan O’Connell stated focus on ALTITUDE AD execution, with Jim Doherty mentioning ongoing work on subcutaneous formulation and next steps.

Q: Pete Stavropoulos inquired about biomarkers and top line results for ALTITUDE.

A: Jim Doherty and Eric Siemers discussed primary outcome measure as iADRS, emphasis on biomarkers, and plan for top line results.

Q: Ting Liu asked about p-Tau-217 biomarker in ALTITUDE screening.

A: Eric Siemers explained use of p-Tau-217 as a screener and relation to amyloid positivity.

Q: Tom Shrader asked about subcu MOA and iADRS vs CDR.

A: Eric Siemers and Jim Doherty discussed iADRS being less subjective, and sabirnetug's focus on soluble A-beta oligomers.

Q: Unidentified Analyst asked about enrollment and subcu results.

A: Jim Doherty and Eric Siemers talked about successful enrollment, baseline characteristics, and positive subcu study results with mild injection site reactions.